Aligos Therapeutics Management
Management criteria checks 3/4
Aligos Therapeutics' CEO is Larry Blatt, appointed in Feb 2018, has a tenure of 6.25 years. total yearly compensation is $1.34M, comprised of 43.7% salary and 56.3% bonuses, including company stock and options. directly owns 2.71% of the company’s shares, worth $1.72M. The average tenure of the management team and the board of directors is 5.3 years and 5.8 years respectively.
Key information
Larry Blatt
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 43.7% |
| CEO tenure | 6.3yrs |
| CEO ownership | 2.7% |
| Management average tenure | 5.3yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$587k | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$82m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$83m |
| Dec 31 2022 | US$2m | US$549k | -US$96m |
| Sep 30 2022 | n/a | n/a | -US$112m |
| Jun 30 2022 | n/a | n/a | -US$126m |
| Mar 31 2022 | n/a | n/a | -US$136m |
| Dec 31 2021 | US$873k | US$549k | -US$128m |
| Sep 30 2021 | n/a | n/a | -US$125m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$116m |
| Dec 31 2020 | US$7m | US$493k | -US$109m |
| Sep 30 2020 | n/a | n/a | -US$92m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$674k | US$475k | -US$52m |
Compensation vs Market: Larry's total compensation ($USD1.34M) is above average for companies of similar size in the US market ($USD667.96K).
Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.
CEO
Larry Blatt (61 yo)
6.3yrs
Tenure
US$1,344,458
Compensation
Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 6.3yrs | US$1.34m | 2.71% $ 1.7m | |
| Executive VP & Chief Scientific Officer | 6yrs | US$836.32k | 0.50% $ 319.2k | |
| Executive VP & Chief Medical Officer | 4.8yrs | US$837.72k | no data | |
| Executive VP & CFO | 3.9yrs | no data | no data | |
| VP and Head of People & Culture | 2.3yrs | no data | no data | |
| Executive Vice President & Chief Development Officer | 5.8yrs | no data | no data | |
| Executive VP & Head of Chemical Operations | 5.8yrs | no data | no data | |
| VP of Early Compound Development & Belgian Site Head | 2.3yrs | no data | no data |
5.3yrs
Average Tenure
57yo
Average Age
Experienced Management: ALGS's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 6.3yrs | US$1.34m | 2.71% $ 1.7m | |
| Independent Director | 5.8yrs | US$12.90k | 0% $ 0 | |
| Lead Independent Director | 5.8yrs | US$93.40k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$67.90k | 0.23% $ 148.3k | |
| Independent Director | 2.5yrs | US$52.90k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$60.40k | 0.076% $ 48.2k |
5.8yrs
Average Tenure
61yo
Average Age
Experienced Board: ALGS's board of directors are considered experienced (5.8 years average tenure).